RANKINGS

POPULAR STOCKS

Ardelyx, Inc.

NasdaqGM:ARDX

Location

United States

Market Cap

USD 863.71 M

Share Price

USD 3.56

Avg Daily Volume

5,353,574

Change (1 day)

-1.39%

Change (1 year)

-39.56%

Change (YTD)

-29.78%

Ardelyx, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 4.00

Ardelyx, Inc. Quick Ratio is 4.00 for the Trailing 12 Months (TTM) ending March 31, 2025, a -2.20% change year over year. Quick ratio measures the short-term obligations coverage with liquid assets; higher ratio indicates strong liquidity position.
  • Ardelyx, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 4.09, a 79.94% change year over year.
  • Ardelyx, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 2.27, a -9.96% change year over year.
  • Ardelyx, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 2.52.
Key data
Date Quick Ratio Current Ratio Interest Coverage Ratio Return on Capital Employed (ROCE)
Market news
NasdaqGM: ARDX

Ardelyx, Inc.

CEO Mr. Michael G. Raab
IPO Date June 19, 2014
Location United States
Headquarters 400 Fifth Avenue
Employees 395
Sector 🏥 Health Care
Industries
Clinical Trials
🧬 Biotechnology
💊 Drugstores & Retail Pharmacies
🌿 Fertilizers
💊 Pharmaceuticals
Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Similar companies

BMRN

BioMarin Pharmaceutical Inc.

USD 55.00

-0.43%

4151.T

Kyowa Kirin Co., Ltd.

USD 16.98

-0.29%

ABBOTINDIA.NS

Abbott India Limited

USD 364.99

2.00%

002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.75

-1.49%

1SXP.F

SCHOTT Pharma AG & Co. KGaA

USD 31.51

-0.12%

688336.SS

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

USD 7.51

0.04%

1513.HK

Livzon Pharmaceutical Group Inc.

USD 3.65

-2.55%

0867.HK

China Medical System Holdings Limited

USD 1.48

3.57%

002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

USD 3.88

2.91%

GLAND.NS

Gland Pharma Limited

USD 19.89

1.04%

000623.SZ

Jilin Aodong Pharmaceutical Group Co., Ltd.

USD 2.26

0.09%

600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

USD 2.56

0.67%

603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

USD 1.50

-0.16%

CONCORDBIO.NS

Concord Biotech Limited

USD 21.21

-6.80%

002019.SZ

Yifan Pharmaceutical Co., Ltd.

USD 1.84

-0.59%

9989.HK

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

USD 0.65

-1.53%

002755.SZ

Beijing Aosaikang Pharmaceutical Co., Ltd.

USD 2.21

-1.66%

NEULANDLAB.NS

Neuland Laboratories Limited

USD 141.34

0.37%

300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

USD 3.57

0.36%

FAE.MC

Faes Farma, S.A.

USD 5.20

0.24%

LLY

Eli Lilly and Company

USD 762.73

-2.84%

ABBV

AbbVie Inc.

USD 185.30

-0.10%

RO.SW

Roche Holding AG

USD 336.78

-0.52%

AZN.L

AstraZeneca PLC

USD 140.24

-1.30%

MRK

Merck & Co., Inc.

USD 79.06

-0.29%

AMGN

Amgen Inc.

USD 289.33

-0.10%

TMO

Thermo Fisher Scientific Inc.

USD 397.88

1.35%

PFE

Pfizer Inc.

USD 23.97

0.38%

GILD

Gilead Sciences, Inc.

USD 108.50

0.46%

SAN.PA

Sanofi

USD 95.88

0.36%

BMY

Bristol-Myers Squibb Company

USD 46.86

0.04%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 49.19

-0.68%

GSK.L

GSK plc

USD 18.89

-2.25%

COR

Cencora, Inc.

USD 293.66

-1.04%

REGN

Regeneron Pharmaceuticals, Inc.

USD 509.72

-0.75%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.23

0.75%

HLN.L

Haleon plc

USD 5.16

0.21%

4502.T

Takeda Pharmaceutical Company Limited

USD 29.34

-0.64%

4568.T

Daiichi Sankyo Company, Limited

USD 22.63

-2.53%

UCB.BR

UCB SA

USD 181.46

0.14%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.57

0.90%

DIVISLAB.NS

Divi's Laboratories Limited

USD 76.09

1.62%

TEVA.TA

Teva Pharmaceutical Industries Limited

USD 17.30

1.37%

INSM

Insmed Incorporated

USD 102.68

3.24%

600436.SS

Zhangzhou Pientzehuang Pharmaceutical., Ltd

USD 27.92

0.34%

WST

West Pharmaceutical Services, Inc.

USD 215.82

-0.98%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 53.56

1.09%

SMMT

Summit Therapeutics Inc.

USD 20.56

1.98%

CIPLA.NS

Cipla Limited

USD 17.31

1.15%

UTHR

United Therapeutics Corporation

USD 290.75

-0.33%

StockViz Staff

June 22, 2025

Any question? Send us an email